Collaborative Work can Lead to Innovation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Collaborative Work can Lead to Innovation


Pharmaceutical Technology Europe
Volume 24, Issue 9


Dr. Ralf Fink
Dear Reader,
In drug development, the majority of new chemical entities are lipophilic and/or poorly soluble. New actives often fail during development due to these challenging properties. The solubilization of actives is therefore an important approach towards improving the bioavailability of a drug molecule in an accepted dosage form.

In this special issue, BASF would like to open up a discussion about solubilization challenges and innovative solutions, focusing on both products and cost-effective production technologies, such as hot-melt extrusion and spray drying. Because innovation is always the result of many, companies such as Catalent, Bend Research and Johnson & Johnson have also contributed with their expertise on this topic.

True to its legacy of innovation, BASF continues to develop new innovative solubilizers, such as Soluplus®. Thus, together with our established portfolio of Kolliphor® solubilizers and Kollisolv® cosolvents, we offer a versatile toolbox capable of coping with the many solubilization challenges facing our industry. This, in combination with our SoluHTS® screening robot, enables the industry to screen and identify the most suitable solubilization excipients faster, thereby shortening their product development time.

In the end, there is no single way out of the "maze of pharmaceutical development." However, the use of new technologies and innovative products may get us out quicker.

Dr. Ralf Fink

Vice-President of Global Marketing,
BASF Pharma Ingredients & Services

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology Europe,
Click here